John V. Heymach, MD, PhD, expands on the efficacy of perioperative durvalumab in the AEGAN trial, the significance of this unique approach for the non–small cell lung cancer treatment paradigm, and future research examining opportunities to build on or intensify the benefit achieved with this regimen.
- Distinguished global experts appointed to strengthen bemcentinib development in STK11m NSCLC - BERGEN, Norway, Feb. 2, 2023 /PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage
/PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet.